NASDAQ:SPPI Spectrum Pharmaceuticals (SPPI) Stock Price, News & Analysis → Claim Your Complimentary Bitcoin Reward (From Crypto Swap Profits) (Ad) Free SPPI Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$1.03▼$1.0350-Day Range$0.94▼$1.0352-Week Range$0.32▼$1.57VolumeN/AAverage Volume1.93 million shsMarket Capitalization$211.41 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Spectrum Pharmaceuticals alerts: Email Address Ad WealthPressA lot of people are making this costly mistakeYou may have heard the saying “options are risky” … And, they can be. But only if you use them the way a lot of folks do. A lot of people think of BUYING speculative options when they talk about options. And BUYING low probability, speculative options is definitely risky… It’s how some folks leverage large sums of money hoping that a stock moves in the “right” direction over a certain period of time. Click here to jump in on the next one About Spectrum Pharmaceuticals Stock (NASDAQ:SPPI)Spectrum Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes oncology drug products. It offers ROLVEDON(Eflapegrastim), a novel long-acting granulocyte colony-stimulating factor for chemotherapy-induced neutropenia. The company develops Poziotinib, a novel irreversible tyrosine kinase inhibitor for non-small cell lung cancer tumors with various mutations. It has co-development, commercialization, and in-license agreements with Hanmi Pharmaceutical Co. Ltd.; a patent and technology license agreement with The University of Texas M.D. Anderson Cancer Center; and license agreement with Therapyx, Inc. The company was formerly known as NeoTherapeutics, Inc. and changed its name to Spectrum Pharmaceuticals, Inc. in December 2002. Spectrum Pharmaceuticals, Inc. was incorporated in 1987 and is headquartered in Boston, Massachusetts.Read More Ad Crypto 101 MediaAltcoin FRENZY Alert…Bitcoin recently crossed the highest price in its 15-year history… Less than 2 years after one of the most vicious crypto market meltdowns we've ever seen! Bitcoin's BOOM also sent shockwaves through the altcoin market, with select coins seeing HUGE moves in a matter of days… Like Fetch.ai, that gained over 350% in just the last 30 days… Click here now to register for the event (FOR FREE!) SPPI Stock News HeadlinesFebruary 21, 2024 | markets.businessinsider.comAssertio Holdings, Inc. Sued for Securities Law Violations – Investors Should Contact Levi & Korsinsky for More Information - ASRTFebruary 21, 2024 | markets.businessinsider.comLevi & Korsinsky Notifies Shareholders of Assertio Holdings, Inc.(ASRT) of a Class Action Lawsuit and an Upcoming DeadlineMarch 29, 2024 | MarketBeat (Ad)Your $200 account credit is about to expireUpdate to MarketBeat All Access and Save $300 on Your Annual SubscriptionFebruary 8, 2024 | markets.businessinsider.comLost Money on Assertio Holdings, Inc.(ASRT)? Join Class Action Suit Seeking Recovery - Contact Levi & KorsinskyFebruary 5, 2024 | markets.businessinsider.comAssertio Holdings, Inc. (NASDAQ: ASRT) INVESTOR ALERT: Berger Montague Advises Investors to Inquire About a Securities Fraud Class ActionFebruary 1, 2024 | stockhouse.comGlancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Assertio Holdings, Inc. (ASRT)February 1, 2024 | markets.businessinsider.comCLASS ACTION NOTICE: Berger Montague Encourages Assertio Holdings, Inc. (ASRT) Investors to Inquire About a Securities Fraud Class ActionJanuary 30, 2024 | stockhouse.comSHAREHOLDER ALERT: Levi & Korsinsky Notifies Assertio Holdings, Inc.(ASRT) Investors of a Class Action Lawsuit and Upcoming DeadlineMarch 29, 2024 | DTI (Ad)Warning: this could blow your mindBuckle up… ‘Cause this might shatter everything you’ve heard about “income trading”. In fact, it’s such an extreme diversion from what most people think of typical income trades that I call it: The Perfect Income Trade You see, most of the income techniques out there target a couple of percent. Maybe 5 - 10 percent if you’re lucky. But this new way of trading income on the world’s top stocks goes after more than 10x that kind of return. And here’s the best news of all: This trade can target an opportunity like that every week. Every single week. Meaning an investor has the chance to “stack up” these more aggressive income trades over and over. If that sounds interesting…January 26, 2024 | tmcnet.comINVESTOR ALERT: Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Assertio Holdings, Inc. (ASRT) InvestorsJanuary 13, 2024 | stockhouse.comINVESTOR ALERT: Levi & Korsinsky Notifies Shareholders of Assertio Holdings, Inc.(ASRT) of a Class Action Lawsuit and an Upcoming DeadlineJanuary 12, 2024 | finance.yahoo.comEye Melanoma Market Size Worth USD 9.56 Billion in 2032 | Emergen ResearchJanuary 10, 2024 | finance.yahoo.comVaccine Adjuvant Market Size Worth USD 1.75 Billion in 2032 | Emergen ResearchJanuary 9, 2024 | msn.comSHAREHOLDER ALERT: Potential Recovery for Assertio Holdings, Inc. (ASRT) InvestorsNovember 9, 2023 | markets.businessinsider.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Assertio Holdings, Inc. - ASRTJuly 24, 2023 | seekingalpha.comBuy Spectrum Pharmaceuticals For Exposure To Assertio HoldingsJuly 8, 2023 | fool.comSpectrum Pharmaceuticals (NASDAQ: SPPI)July 3, 2023 | benzinga.comMoore Kuehn Encourages SYNH, SPPI, ARNC and EMBK Investors to Contact Law FirmJune 30, 2023 | finance.yahoo.comSPPI - Spectrum Pharmaceuticals, Inc.May 26, 2023 | msn.comHC Wainwright & Co. Reiterates Spectrum Pharmaceuticals (SPPI) Neutral RecommendationMay 17, 2023 | finance.yahoo.comSpectrum Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price RequirementMay 15, 2023 | msn.comJefferies Downgrades Spectrum Pharmaceuticals (SPPI)May 14, 2023 | finance.yahoo.comNews Flash: Analysts Just Made A Captivating Upgrade To Their Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) ForecastsMay 10, 2023 | finance.yahoo.comQ1 2023 Assertio Holdings Inc Earnings CallMay 9, 2023 | msn.comSpectrum Pharmaceuticals rises as co. says its Q1 net sales up 54% Q/QMay 9, 2023 | finance.yahoo.comSpectrum Pharmaceuticals (SPPI) Reports Q1 Loss, Tops Revenue EstimatesMay 5, 2023 | markets.businessinsider.comB.Riley Financial Remains a Hold on Spectrum Pharmaceuticals (SPPI)See More Headlines Receive SPPI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Spectrum Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/10/2021Today3/28/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryBiotechnology Current SymbolNASDAQ:SPPI CUSIP84763A10 CIK831547 Webwww.sppirx.com Phone(617) 586-3900Fax702-260-7405Employees86Year Founded2002Profitability EPS (Most Recent Fiscal Year)($0.36) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-75,400,000.00 Net MarginsN/A Pretax Margin-263.04% Return on Equity-218.44% Return on Assets-66.16% Debt Debt-to-Equity RatioN/A Current Ratio2.71 Quick Ratio2.38 Sales & Book Value Annual Sales$10.11 million Price / Sales20.91 Cash FlowN/A Price / Cash FlowN/A Book Value$0.15 per share Price / Book6.87Miscellaneous Outstanding Shares205,250,000Free Float199,704,000Market Cap$211.41 million OptionableOptionable Beta2.15 Social Links 7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleGrowth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.Get This Free Report Key ExecutivesMr. Thomas J. Riga (Age 48)Pres, CEO & Director Comp: $1.07MMs. Nora E. Brennan (Age 54)Exec. VP & CFO Comp: $46.25kMr. Keith M. McGahan J.D. (Age 47)L.L.M., Exec. VP, Chief Legal Officer & Corp. Sec. Comp: $948.26kMr. Michael A. GrabowExec. VP & Chief Bus. OfficerDr. Lyndah K. Dreiling M.B.A.M.D., Sr. VP of Clinical Devel.Key CompetitorsMerrimack PharmaceuticalsNASDAQ:MACKVanda PharmaceuticalsNASDAQ:VNDARigel PharmaceuticalsNASDAQ:RIGLXOMANASDAQ:XOMAVerastemNASDAQ:VSTMView All CompetitorsInsidersNora BrennanSold 32,387 sharesTotal: $35,625.70 ($1.10/share) SPPI Stock Analysis - Frequently Asked Questions Should I buy or sell Spectrum Pharmaceuticals stock right now? 3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Spectrum Pharmaceuticals in the last year. There are currently 3 hold ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" SPPI shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in SPPI, but not buy additional shares or sell existing shares. View SPPI analyst ratings or view top-rated stocks. How were Spectrum Pharmaceuticals' earnings last quarter? Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) issued its quarterly earnings data on Wednesday, November, 10th. The biotechnology company reported ($0.21) earnings per share for the quarter, beating analysts' consensus estimates of ($0.28) by $0.07. During the same period last year, the business posted ($0.37) earnings per share. What ETF holds Spectrum Pharmaceuticals' stock? IQ Merger Arbitrage ETF holds 1,389,760 shares of SPPI stock, representing 0.29% of its portfolio. What is Joseph Turgeon's approval rating as Spectrum Pharmaceuticals' CEO? 2 employees have rated Spectrum Pharmaceuticals Chief Executive Officer Joseph Turgeon on Glassdoor.com. Joseph Turgeon has an approval rating of 47% among the company's employees. This puts Joseph Turgeon in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Spectrum Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Spectrum Pharmaceuticals investors own include Inovio Pharmaceuticals (INO), Verastem (VSTM), Exelixis (EXEL), SCYNEXIS (SCYX), TG Therapeutics (TGTX), Advanced Micro Devices (AMD), OPKO Health (OPK), Bausch Health Companies (BHC), Sorrento Therapeutics (SRNE) and Zynerba Pharmaceuticals (ZYNE). This page (NASDAQ:SPPI) was last updated on 3/29/2024 by MarketBeat.com Staff From Our PartnersDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsTop Project Outperforms BTC in 2023…Crypto 101 MediaMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceAI Cracks Open Largest Untapped Energy Reserve on EarthBanyan Hill PublishingThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading Academy“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisoryAI healthcare stock poised for 36,996% growth?Behind the MarketsBill Gates is all about this tiny $2 stockTimothy Sykes Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Spectrum Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.